Home EU
Identifiez-vous /
Enregistrez-vous
0
Portefeuille

Êtes-vous inscrit? Accéder Avez-vous oublié votre mot de passe?

Non enregistré? Enregistrez-vous

Trouve le conseiller
fait pour toi
Vérifiez votre portefeuille
- Calculer le risque et le rendement d'un portefeuille de titres
- Calcul retraite complémentaire
Conseils et nouvelles des professionnels
de la finance - news
Classements Fonds / ETFs / Actions
Apprendre la finance
- Glossaire de la finance
- Apprendre à investir
  Les principaux concepts de la finance
Bureau d'études
Qui sommes-nous
Inscrivez-vous à la newsletter

Partager

Abcellera Biologics Inc. - actualités publiées 203 - lectures 12.273

RETOUR

Abcellera Biologics Inc.

Abcellera Biologics Inc.

AbCellera to Present at Upcoming Investor Conferences in November

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Abcellera Biologics Inc. published this content on October 22, 2024 , and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on October 23, 2024 at 13:38:36.976 .

Abcellera Biologics Inc.

Abcellera Biologics Inc.

AbCellera to Present at Upcoming Investor Conferences in November 2024

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced that executives from the Company will be presenting at the following investor conferences: Stifel Healthcare Conference on Monday, November 18, 2024, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:00 a.m. Pacif ...

Abcellera Biologics Inc.

Abcellera Biologics Inc.

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced an upcoming poster presentation on its T-cell engager platform at the SITC 39th Annual Meeting, to be held November 6 to 10 at the George R. Brown Convention Center in Houston, Texas. Details on AbCellera's poster presentation at SITC are as follows: Title: Profiling bispecific T-cell engag ...

Abcellera Biologics Inc.

Abcellera Biologics Inc.

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

The text version of this document is not available. You can access the original document here . Disclaimer Abcellera Biologics Inc. published this content on September 26, 2024 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on September 26, 2024 at 20:16:52 UTC .

Abcellera Biologics Inc.

Abcellera Biologics Inc.

Statement of Changes in Beneficial Ownership - Form 4

Ownership Submission FORM 4 Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investmen ...

Abcellera Biologics Inc.

Abcellera Biologics Inc.

AbCellera to Present at Upcoming Investor Conferences in September

The text version of this document is not available. You can access the original document here . Attachments Original Link Permalink Disclaimer Abcellera Biologics Inc. published this content on 29 August 2024 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on August 29, 2024 at 20:14:16 UTC .

Abcellera Biologics Inc.

Abcellera Biologics Inc.

Quarterly Report for Quarter Ending June 30, 2024 (Form 10-Q)

abcl-20240630 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _________________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT ...

Abcellera Biologics Inc.

Abcellera Biologics Inc.

AbCellera Reports Q2 2024 Business Results Form 8 K

AbCellera Reports Q2 2024 Business Results 08/06/2024 VANCOUVER, British Columbia - AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "This quarter, we made important progress on our internal pipeline and aim to submit applicati ...

Abcellera Biologics Inc.

Abcellera Biologics Inc.

Second Quarter 2024 Presentation

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Abcellera Biologics Inc. published this content on 06 August 2024 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 06 August 2024 21:33:36 UTC .

Abcellera Biologics Inc.

Abcellera Biologics Inc.

AbCellera Reports Q2 2024 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "This quarter, we made important progress on our internal pipeline and aim to submit applications for clinical trials for ABCL635 a ...

Abcellera Biologics Inc.

Abcellera Biologics Inc.

Second Quarter 2024 Press Release

2215 Yukon St . Vancouver, BC Canada, V5Y 0A1 T 1. 604.559.9005 abcellera.com NEWS RELEASE AbCellera Reports Q2 2024 Business Results 8/6/2024 VANCOUVER, British Columbia--(BUSINESSWIRE)-- AbCellera (Nasdaq: ABCL) today announced nancial results for the second quarter of 2024. All nancial information in this press release is reported in U.S. dollars, unless otherwise indicated ...

Abcellera Biologics Inc.

Abcellera Biologics Inc.

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with Eli Lilly and Company (Lilly) to discover therapeutic antibodies for programs in immunology, cardiovascular disease, and neuroscience. The expansion builds upon the successful research collaboration established in March 2020, which includ ...

Abcellera Biologics Inc.

Abcellera Biologics Inc.

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

The text version of this document is not available. You can access the original document here . Attachments Original Link Permalink Disclaimer Abcellera Biologics Inc. published this content on 25 June 2024 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 25 June 2024 20:12:08 UTC .

Abcellera Biologics Inc.

Abcellera Biologics Inc.

Statement of Changes in Beneficial Ownership - Form 4

Ownership Submission FORM 4 Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investmen ...

Abcellera Biologics Inc.

Abcellera Biologics Inc.

Statement of Changes in Beneficial Ownership - Form 4

Ownership Submission FORM 4 Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investmen ...

1
2
3
>>
10

Utilisateur "Membre"

En plus des services gratuits :

· Contacter un conseiller financier · Forum financier et Newsletter

Vous pourrez profiter de tous les autres services
de notre plateforme !

Vérifiez votre portefeuille

Nous calculons:

Le rendement et le risque attendu
Le portefeuille efficient qui se rapproche le plus de tes attentes de risque/rendement
10 portefeuilles optimisés en pondérant les titres que vous avez saisis
Performance PIC et PAC
Sauvegarder les portefeuilles créés

Calculer votre retraite complémentaire

À combien s'élèvera ma retraite complémentaire en versant € ... par mois ?
Combien dois-je verser par mois pour avoir un revenu de € ... par mois ?

Classements Fonds/ETFs/Actions

Classement Fonds/ETFs
Classement Actions Françaises
Les meilleurs Fonds par coût/risque/rendement
Tous les Fonds communs/ETF
Actions françaises et internationales

Notifications personnalisées

Choisissez des thèmes, des professionnels et des entreprises. Vous recevrez une notification pour toute nouvelle publiée sur notre plateforme et pour toute nouvelle concernant les titres que vous avez sauvegardés dans votre portefeuille.

Fiches produits

Chaque titre individuel se voit attribuer une carte contenant :

Indicateurs de risque
Le rendement attendu
Performances du PIC et du PAC pour la période choisie

Apprendre la finance

Glossaire de la finance
Les principaux concepts de la finance pour investir en connaissance de cause

Bureau d'études

Titres Top: les 10 titres les plus populaires du mois dans les portefeuilles créés par les utilisateurs de MoneyController
Asset Allocation: rapports basés sur les portefeuilles créés au cours du mois par les utilisateurs de MoneyController
Les 50 App Financières les plus téléchargées

Actualités de la Bourse

Tous les communiqués de presse des sociétés cotées sur les marchés français et étrangers

€2,99par mois

Vous pouvez l'annuler à tout moment.

Identifiez-vous ou Enregistrez